Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1921 in Advanced Solid Tumors
NCT05594875Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Dec 2022
- Primary completion
- Apr 2024
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tizetatug rezetecan in solid tumor (advanced stage), sponsored by Atridia Pty Ltd. Primary endpoints: Number of subjects with adverse events (AEs), Number of subjects with laboratory tests findings of potential clinical importance and 2 more. Started Dec 2022; status: completed.
02
Drugs
tizetatug rezetecan
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05594875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05594875.